InMed PharmaceuticalsINM -0.61%29 Piotroski F-Score is 4 as of Jul. 10, 2026, which is 33% above its 10-year median of 3.00. GuruFocus rates INM with a GF Score™ of 29/100 and a GF Value™ of $0.93 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 980 Drug Manufacturers companies, InMed Pharmaceuticals ranks worse than 61.02% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
InMed Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for InMed Pharmaceuticals's Piotroski F-Score or its related term are showing as below:
INM'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 3 Max: 5
Current: 4
During the past 13 years, the highest Piotroski F-Score of InMed Pharmaceuticals was 5. The lowest was 1. And the median was 3.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
InMed Pharmaceuticals Piotroski F-Score Related Terms
InMed Pharmaceuticals Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for InMed Pharmaceuticals's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INM vs SNOA, CVSI, PRFX: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InMed Pharmaceuticals Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where InMed Pharmaceuticals's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
InMed Pharmaceuticals's current Net Income (TTM) was -8.51.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
InMed Pharmaceuticals's current Cash Flow from Operations (TTM) was -7.46.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
InMed Pharmaceuticals's return on assets of this year was -0.9169181. InMed Pharmaceuticals's return on assets of last year was -0.62220226.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
InMed Pharmaceuticals's gearing of this year was 0.00264749. InMed Pharmaceuticals's gearing of last year was 0.03921092.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
InMed Pharmaceuticals's current ratio of this year was 3.11533243. InMed Pharmaceuticals's current ratio of last year was 3.48558999.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
InMed Pharmaceuticals's number of shares in issue this year was 4.048. InMed Pharmaceuticals's number of shares in issue last year was 1.096.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
InMed Pharmaceuticals's gross margin of this year was 0.80342874. InMed Pharmaceuticals's gross margin of last year was 0.38797814.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
InMed Pharmaceuticals's asset turnover of this year was 0.74170259. InMed Pharmaceuticals's asset turnover of last year was 0.2739726.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
0
+
0
+
1
+
1
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
InMed Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.
InMed Pharmaceuticals (INM) has a Piotroski F-Score of 4 as of Jul. 10, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on InMed Pharmaceuticals and its competitors. This is 33% above median its historical median of 3.00. Over the past decade, InMed Pharmaceuticals' Piotroski F-Score has ranged from 1.00 to 5.00. According to the industry distribution chart, InMed Pharmaceuticals ranks #598 out of 980 companies in the Drug Manufacturers industry, placing it in the top 61%.
Is InMed Pharmaceuticals' Piotroski F-Score too high?
InMed Pharmaceuticals' current Piotroski F-Score of 4 is 33% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 5.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. InMed Pharmaceuticals' value of 4 is 20% below this industry median. Based on the distribution chart, InMed Pharmaceuticals ranks #598 out of 980 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' Piotroski F-Score compare to SNOA and CVSI?
According to the Drug Manufacturers industry distribution chart, InMed Pharmaceuticals ranks #598 out of 980 companies for Piotroski F-Score. This places InMed Pharmaceuticals in the lower half of its industry. The industry median Piotroski F-Score is 5.00. InMed Pharmaceuticals' value of 4 is 20% below this benchmark. Historically, InMed Pharmaceuticals' own Piotroski F-Score has ranged from 1.00 to 5.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, InMed Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InMed Pharmaceuticals's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on InMed Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InMed Pharmaceuticals's current Piotroski F-Score is 4, which is 33% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, InMed Pharmaceuticals (INM) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.93, compared to a current price of $1.65 — trading 77.4% above its estimated fair value. The current Piotroski F-Score is 4, which is 33% above median its 10-year median of 3.00 and 20% below the Drug Manufacturers industry median of 5.00. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For InMed Pharmaceuticals (INM), the current Piotroski F-Score is 4 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InMed Pharmaceuticals (INM) Overvalued in 2026?
Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued.
The current stock price of $1.65 is trading 77.4% above its estimated GF Value™ of $0.93.
GuruFocus considers InMed Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for INM:
Piotroski F-Score: 4 (33% above median its 10-year median of 3.00)
GF Value™: $0.93 vs. price of $1.65 (77.4% above fair value)
Industry Position: 20% below the Drug Manufacturers median (#598 of 980)
No single metric tells the full story. See the INM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score
Get the complete analysis for INM
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INM has been successfully added to your 
